[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"concurrent-chemoradiation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:concurrent-chemoradiation-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100608330","phase-2-adebrelimab-plus-chemoradiotherapy-followed-by-adebrelimab-maintenance-in-limited-stage-sclc-100608330",false,"NCT07200154","Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC","A Single-arm、Exploratory Study of Adebrelimab in Combination With Chemoradiotherapy Followed by Adebrelimab Maintenance in Patients With Limited-stage Small-cell Lung Cancer","Inclusion Criteria:\n\n* Age 18-75 years, either sex. Histologically or cytologically confirmed limited-stage small-cell lung cancer (LS-SCLC) defined by Veterans Administration Lung Group (VALG) two-stage system.\n\nAvailability of either an archival tumour-tissue block\u002Fslides or a newly obtained biopsy from a lesion that has not previously been irradiated.\n\n≤ 2 prior cycles of chemotherapy or chemotherapy-naïve. ECOG performance-status 0 or 1. At least one measurable lesion per RECIST 1.1: ≥ 10 mm in longest diameter for non-nodal lesions or ≥ 15 mm in short axis for lymph-node lesions on CT scan.\n\nEstimated life expectancy ≥ 3 months. Adequate pulmonary function (as judged by the investigator).\n\nAdequate major organ function defined as:\n\nHaematology: Hb ≥ 90 g\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL. Biochemistry: serum albumin ≥ 30 g\u002FL; ALT and AST \\\u003C 3 × ULN; total bilirubin ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN.\n\nWomen of child-bearing potential must have a negative serum or urine pregnancy test within 14 days before enrolment and must use effective contraception from screening until ≥ 8 weeks after the last study-dose; men must be surgically sterile or agree to use effective contraception during the same period.\n\nVoluntary informed consent signed; willing and able to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n* Prior solid-organ, allogeneic stem-cell or planned transplantation. Immunosuppressive therapy ≤ 14 days before first adebrelimab dose (except intranasal\u002Finhaled corticosteroids or physiological systemic doses equivalent to ≤ 10 mg\u002Fday prednisolone).\n\nKnown hypersensitivity to etoposide, cisplatin, adebrelimab, their excipients, or severe allergic reaction to any other monoclonal antibody.\n\nLive-attenuated vaccine within 4 weeks before first dose or intent to receive one during the study.\n\nActive autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyper-\u002Fhypothyroidism).\n\nUncontrolled asthma requiring bronchodilators or other systemic therapy (childhood asthma fully resolved and requiring no intervention in adulthood is allowed).\n\nUrinalysis ≥ ++ protein or 24-h urine protein ≥ 1.0 g. Prior malignancy except adequately treated basal-cell or squamous-cell skin carcinoma or cervical carcinoma in situ.\n\nHIV infection or known AIDS. Within 6 months before enrolment: myocardial infarction, severe\u002Funstable angina, NYHA class ≥ II heart failure, poorly controlled arrhythmia (including QTcF \\> 450 ms \\[men\\] or \\> 470 ms \\[women\\] by Fridericia), symptomatic congestive heart failure.\n\nSystemic anti-infective therapy (IV antibiotics, antifungals, or antivirals) within 4 weeks before first dose, or unexplained fever \\> 38.5 °C during screening or before first dose.\n\nActive hepatitis B (HBV DNA ≥ 500 IU\u002FmL), hepatitis C (anti-HCV positive and HCV-RNA detectable), or HBV\u002FHCV co-infection.\n\nParticipation in another interventional clinical trial within 4 weeks before first dose.\n\nKnown history of substance abuse or recreational drug use. Any severe medical, psychiatric, or laboratory abnormality that, in the investigator's opinion, could increase study-related risk or interfere with results.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by adebrelimab maintenance.",[27,28],"Limited-stage Small-cell Lung Cancer","Concurrent Chemoradiation Therapy",[30,31,28],"limited-stage small-cell lung cancer","Immune checkpoint inhibitors","NOT_YET_RECRUITING","2025-09-22",{"date":35,"type":36},"2025-09-30","ACTUAL",{"date":35,"type":21},{"date":39,"type":21},"2028-09",{"name":41,"class":42},"Peking University Cancer Hospital & Institute","OTHER"]